Discover
APGE
Apogee Therapeutics, Inc.
133.65
2 x 132.84
1 x 134.00
bid
ask
+
0.08
0.06%
22 @ 07:20 PM
133.41 -0.24 (0.18%)
| Ytd | 77.07% | |
| 1y | 261.02% |
133.36
day range
133.75
34.34
52 week range
133.87
| Open | 133.46 | Prev Close | 133.57 | Low | 133.36 | High | 133.75 | Mkt Cap | 8.25B |
| Vol | 787.80K | Avg Vol | 2.52M | EPS | -4.33 | P/E | -30.87 | Forward P/E | -25.74 |
| Beta | 0.33 | Short Ratio | 9.81 | Inst. Own | 116.51% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 95.33 | 200-d Avg | 75.10 | 1yr Est | 130.53 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-11 | 2026-03 | 0 | N/A | N/A | N/A |
| 2026-03-02 | 2025-12 | 0 | N/A | N/A | N/A |
| 2025-11-10 | 2025-09 | 0 | N/A | 0.03 | 2.63% |
| 2025-11-10 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-11 | 2025-06 | 0 | N/A | -0.1 | -9.71% |
| 2025-08-11 | 2025-06 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-24 | Stifel | Downgrade | Buy | Hold |
| 2026-06-24 | TD Cowen | Downgrade | Buy | Hold |
| 2026-06-24 | Guggenheim | Downgrade | Buy | Neutral |
| 2026-06-24 | Mizuho | Downgrade | Outperform | Neutral |
| 2026-06-23 | Deutsche Bank | Downgrade | Buy | Hold |
| 2026-06-23 | Citigroup | Downgrade | Buy | Neutral |
Profile
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-30 | DAMBKOWSKI CARL | Officer | 177.87K | Conversion of Exercise of derivative security |
| 2026-01-21 | FAIRMOUNT FUNDS MANAGEMENT LLC | Unknown | 0.00 | Sale |
| 2026-04-30 | HENDERSON JANE | Chief Financial Officer | 173.37K | Sale |
| 2026-06-21 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 1.02M | Sale |
| 2024-12-11 | MCKENNA MARK C | Director | 20.00K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | T. Rowe Price Investment Management, Inc. | 10.30M | 1.38B | 16.64% |
| 2026-03-30 | FMR, LLC | 9.26M | 1.24B | 14.96% |
| 2026-03-30 | Venrock Adviser, LLC | 8.49M | 1.13B | 13.72% |
| 2026-03-30 | Wellington Management Group, LLP | 4.38M | 584.46M | 7.07% |
| 2026-03-30 | Blackrock Inc. | 4.09M | 545.72M | 6.60% |
| 2026-03-30 | RTW Investments LP | 2.78M | 371.60M | 4.49% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 5.30M | 707.38M | 8.56% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.84M | 245.82M | 2.97% |
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.84M | 245.58M | 2.97% |
| 2026-04-29 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.49M | 199.12M | 2.41% |
| 2026-05-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.26M | 167.73M | 2.03% |
| 2026-03-30 | JNL Series Trust-JNL/T. Rowe Price Capital Appreciation Fund | 1.13M | 150.36M | 1.82% |